About us
Назад
About us
History
Structure
Management
Manufacturing
Назад
Manufacturing
API & FDF Experimental Producton
Сustom chemistry services
Preclinical research services
Biotechnological Producton (BioIntegrator)
Portfolio
Назад
Portfolio
BioIntegrator
Viriom
Chromis
Aviron, Avivir
CardioSystemPharma
NewVac
Avineuro
Infrastructure
Назад
Infrastructure
ChemRar Research and Development Institute
Chemical Diversity Research Institute
API-Technology
Biotechnological production (BioIntegrator)
Technopark management
News
Contacts
RUS
ENG
+7 (495) 925-30-74
Home
>>
Мероприятия
Мероприятия
CONTENTS
Company news
27.12.2021
ChemRar Group announces the Russian Avifavir® drug is effective against variants of COVID-19, including Delta and Omicron
17.06.2021
Avifavir® for the treatment of COVID-19 is rated among Russia’s TOP 100 Inventions
08.06.2021
Leading infectious disease experts in Russia recognized the efficacy of Avifavir®
24.03.2021
Avifavir obtains its first registration in Asia
10.03.2021
Chromis published results of a multi-center open label post-marketing clinical study in 940 COVID-19 patients confirming efficacy of Avifavir at CROI2021
All news
Ajax Call Form
Loading...
Close